CTIS.eu › Cities › Finland › Tampere
Tampere
Finland
259 total trials
111 recruiting
2023-503571-19-00
5
2022-01-20
Chronic Obstructive Pulmonary Disease (COPD)
2023-507688-20-00
5
2021-12-03
Participants with completely resected Stage III or Stage IV melanoma
2022-500752-39-00
5
2021-11-25
Prevention of Respiratory syncytial virus (RSV) infection in infants a
2023-503280-42-00
5
2021-06-01
Metastatic Clear Cell Renal Cell Carcinoma
2023-510230-84-00
5
2021-05-28
Severe asthma with an eosinophilic phenotype
2022-501252-28-00
4
2021-04-15
Non Small Cell Lung cancer
2024-512837-34-00
5
2020-10-14
Episodic and Chronic Migraine
2022-502361-15-00
5
2019-12-12
Moderate-to-Severe Plaque Psoriasis
2023-507669-24-00
5
2019-11-05
Chronic lymphocytic leukemia
2024-516054-21-00
5
2019-10-25
Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Mod
2023-503673-38-00
5
2019-05-24
Adults at high risk of cardiovascular events without prior MI or strok
2024-512158-12-00
5
2018-12-14
Bladder Cancer
Muscle-Invasive Bladder Cancer
2022-502938-30-00
5
2018-12-10
Moderate and Severe Atopic Dermatitis
2024-517439-39-00
7
2018-03-19
Metastatic castration-resistant prostate cancer.
2023-510557-42-00
4
2017-07-10
chronic lymphocytic leukemia
2022-501251-81-00
5
2017-06-08
Renal cell carcinoma
2023-504761-23-00
5
2014-11-19
Advanced or metastatic renal cell carcinoma
2023-506487-13-00
5
Hormone receptor-positive, her2-negative advanced/metastatic breast ca
2024-512477-27-00
4
Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primar
Showing 241–259 of 259 trials